|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.740 USD | -4.10% |
|
-6.50% | -70.80% |
| 30/06 | Plus Therapeutics, Inc. - Special Call | |
| 30/06 | Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress | CI |
| Market Cap | 2.57Cr 2.25Cr 2.08Cr 1.91Cr 3.61Cr 247.91Cr 3.69Cr 25Cr 9.76Cr 121.41Cr 9.67Cr 9.46Cr 417.97Cr | P/E 2026 * |
-0.95x | P/E 2027 * | -1.56x |
|---|---|---|---|---|---|
| Enterprise Value | 2.57Cr 2.25Cr 2.08Cr 1.91Cr 3.61Cr 247.91Cr 3.69Cr 25Cr 9.76Cr 121.41Cr 9.67Cr 9.46Cr 417.97Cr | EV / Sales 2026 * |
4.09x | EV / Sales 2027 * | 1.34x |
| Free-Float |
98.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Plus Therapeutics, Inc.
| 1 day | -4.10% | ||
| 1 week | -6.50% | ||
| Current month | -14.42% | ||
| 1 month | -13.23% | ||
| 3 months | -41.47% | ||
| 6 months | -48.02% | ||
| Current year | -70.80% |
| 1 week | 3.58 |  | 4.42 |
| 1 month | 3.58 | | 4.51 |
| Current year | 2.9 | | 15.32 |
| 1 year | 2.9 | | 23.42 |
| 3 years | 2.9 | | 80.25 |
| 5 years | 2.9 | | 975 |
| 10 years | 2.9 | | 4,29,377.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 02/04/2014 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 06/02/2020 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 21/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 01/10/2002 |
Richard Hawkins
CHM | Chairman | 77 | 25/01/2018 |
| Director/Board Member | 66 | 01/01/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/07/26 | Fiscal year | Director | 1,844 | 0.0269% | ||
| 01/07/26 | Fiscal year | Chief Financial Officer | 5,970 | 0.0870% | ||
| 01/07/26 | Fiscal year | Chief Executive Officer | 32,878 | 0.4791% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.10% | -6.50% | -60.94% | -92.88% | 2.57Cr | |
| +3.90% | -0.39% | +376.72% | +599.59% | 3.96TCr | |
| -1.70% | +4.46% | +7.46% | +57.67% | 3.47TCr | |
| -2.01% | -0.76% | +26.35% | -6.83% | 3.44TCr | |
| +0.06% | +0.34% | +2.32% | +29.30% | 2.71TCr | |
| +0.46% | -3.49% | - | - | 1.62TCr | |
| -0.04% | -0.09% | +68.48% | +117.39% | 1.54TCr | |
| +1.12% | +1.91% | +15.90% | +19.65% | 1.41TCr | |
| 0.00% | +1.36% | +15.74% | -30.62% | 1.3TCr | |
| -0.08% | -3.01% | +1,271.69% | +649.69% | 1.18TCr | |
| Average | -0.24% | -0.62% | +191.53% | +149.22% | 2.06TCr | |
| Weighted average by Cap. | +0.24% | +0.36% | +171.40% | +187.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 62.95L 55.01L 50.77L 46.79L 88.2L 61Cr 90.15L 6.07Cr 2.39Cr 30Cr 2.36Cr 2.31Cr 102.21Cr | 1.91Cr 1.67Cr 1.54Cr 1.42Cr 2.68Cr 184.33Cr 2.74Cr 18Cr 7.26Cr 90Cr 7.19Cr 7.03Cr 310.78Cr |
| Net income | -2.68Cr -2.34Cr -2.16Cr -1.99Cr -3.75Cr -258.09Cr -3.84Cr -26Cr -10Cr -126.4Cr -10Cr -9.84Cr -435.14Cr | -1.85Cr -1.61Cr -1.49Cr -1.37Cr -2.59Cr -177.72Cr -2.64Cr -18Cr -7Cr -87Cr -6.93Cr -6.78Cr -299.64Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | $3.740 | -4.10% | 2,15,179 |
| 16/26/16 | $3.900 | -4.41% | 81,584 |
| 15/26/15 | $4.080 | -4.67% | 1,54,136 |
| 14/26/14 | $4.280 | +2.64% | 3,70,991 |
| 13/26/13 | $4.170 | +4.25% | 3,75,091 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PSTV Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
